Liver micro-RNAs and their role in different HCV genotype infections

Authors
M. Shafaati 1
M. Jamalidoust 2
M. ziyaeyan 2
M. Kargar 3
E. Arefian 4
1 Young Researchers Club, Department of Microbiology Management, College of Science Jahrom branch, Islamic Azad University, Jahrom, Fars, Iran
2 Department of virology, Prof. Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3 Department of Microbiology, Faculty of Sciences, Islamic Azad University, Jahrom Branch, Iran.
4 Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran
Abstract
Hepatitis C virus (HCV) is a common cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The combination of ribavirin and peg-interferon, as standard treatment for HCV infection, seems very promising. Many studies have revealed that despite following standard HCV treatment, a high proportion of HCV genotypes 1 and 4 poorly attain (42% to 46%) the SVR condition, whereas it is somehow easier for HCV genotypes 2 and 3 (76%-82%). Overall, genotypes 1 and 4 antiviral therapies must be continued up to one year to achieve SVR, whereas in individuals infected with genotypes 2 and 3 must continue therapy for six months. Since 2011, direct-acting antiviral agents (DAA) have been introduced that target the HCV-encoded proteins which are vital for replication of the virus. The first generation of DAA, telaprevir, in combination with peg-interferon and ribavirin, more efficiently inhibits replication of genotype 1. Although the level of DAA SVR rate is high, the new treatment has some undesirable adverse effects. Micro-RNAs (miRNAs), as the new HCV drug approach, open a new insight into the treatment of non-responder HCV patients. Altered expression of miRNAs is involved in the aspects of HCV infection and HCC. In the current review, we attempt to better understand the HCV life cycle, liver miRNAs, and their role in this viral infection.

Keywords

[1]  Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H, Nikbin M, Nabavi M, Adibi P, Ziaee M, Behnava B, Rezaee-Zavareh MS, Colombo M, Massoumi H, Bizri AR, Eghtesad B, Amiri M, Namvar A, Hesamizadeh K, Malekzadeh R. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon 2016; 16(8): e40959.
[2]  Elberry MH, Darwish NHE, Mousa SA. Hepatitis C virus management: potential impact of nanotechnology. Virology Journal 2017; 14: 88.
[3]  Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: the viruses and their replication. In: Fields virology. Edited by Knipe DM, Howley PM. 5th edition, Philadelphia: Lippincott-Raven Publishers, 2007; p: 991-1041.
[4]  Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13(2): 223-35.
[5]  Ishida H, Tatsumi T, Hosui A, Nawa T, Kodama T, Shimizu S, Hikita H, Hiramatsu N, Kanto T, Hayashi N, Takehara T. Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem Biophys Res Commun 2011; 412(1): 92-7.
[6]  Han SH, Kim SJ, Kim EJ, Kim TE, Moon JS, Kim GW, Lee SH, Cho K, Yoo JS, Son WS, Rhee JK, Han SH, Oh JW. Phosphorylation of hepatitis C virus RNA polymerases ser29 and ser42 by protein kinase C-related kinase 2 regulates viral RNA replication. J Virol 2014; 88(19): 11240-52.
[7]  Pallaoro M, Lahm A, Biasiol G, Brunetti M, Nardella C, Orsatti L, Bonelli F, Orrù S, Narjes F, Steinkühler C. Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein. J Virol 2001; 75(20): 9939-46.
[8]  Shrivastava S, Steele R, Ray R, Ray RB. MicroRNAs: Role in Hepatitis C Virus pathogenesis. Genes Dis 2015; 2(1): 35-45.
[9]  Fields BN, Knipe DM, Howley PM. Fields Virology. 5th Edition, Wiley publisher, 2007, Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, ©2007. Available from: www.worldcat.org/title/fields-virology/oclc/ 71812790
[10] Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5(6): 453-63.
[11] Fields BN, Knipe DM. Fundamental Virology. 1st ed, Wiley publisher, 1991; Philadelphia: Lippincott Williams & Wilkins, ©2001.
[12] Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: the viruses and their replication. In: Fields virology. Edited by Knipe DM, Howley PM. 5th Edition, Philadelphia: Lippincott-Raven Publishers, 2007; p: 931-59.
[13] Glenn JS. Molecular virology of the hepatitis C virus: implication for novel therapies. Infect Dis Clin North Am 2006; 20(1): 81-98.
 
[14] Zhang Y, Corver J, Chipman PR, Zhang W, Pletnev SV, Sedlak D, Baker TS, Strauss JH, Kuhn RJ, Rossmann MG. Structures of immature flavivirus particles. EMBO J 2003; 22(11): 2604-13.
 
[15] Masciopinto F, Freer G, Burgio VL, Levy S, Galli-Stampino L, Bendinelli M, Houghton M, Abrignani S, Uematsu Y. Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology 2002; 304(2): 187-96.
[16] Whitehill BC. Genetic Variants In Interferon-Induced Genes and HCV Recurrence after Liver Transplantation. M.Sc. Thesis, Richmond, Virginia: Virginia Commonwealth University, 2007. Available from: https://scholarscompass.vcu.edu/cgi/viewcontent.cgi? referer=https://www.google.com/&httpsredir=1&article=2209&context=etd
[17] Brass V, Moradpour D, Blum HE. Molecular virology of hepatitis C virus (HCV): 2006 update. Int J Med Sci 2006; 3(2): 29-34.
[18] Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med 2005; 8(2): 84-90.
[19] Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3(2): 41-6.
[20] Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59(1): 318-27.
[21] Yasui K, Okanoue T, Murakami Y, Itoh Y, Minami M, Sakamoto S, Sakamoto M, Nishioji K. Dynamics of hepatitis C viremia following interferon-alpha administration. J Infect Dis 1998; 177(6): 1475-9.
[22] Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Kinoshita M, Hadama T. Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol 1997; 26(1): 6-13.
[23] Franciscus A. A Guide to: Understanding Hepatitis C. HCSP Guides, 2017; p: 1-18. Available from: http://hcvadvocate.org/ hepatitis/factsheets_pdf/HCV_Guide.pdf
[24] Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74(Pt 11): 2391-9.
[25] Jamalidoust M, Namayandeh M, Asaei S, Aliabadi N, Ziyaeyan M. Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR. World J Gastroenterol 2014; 20(19): 5897-902.
[26] Jamalidoust M, Namayandeh M, Zare M, Ziyaeyan M. Assessment of HCV Infection in Suspected Orphans Newborns by Real-Time PCR and HCV-Core Ag-Elisa. Journal of Fasa University of Medical Sciences 2015; 5(2): 196-201.
[27] Khodabandehloo M, Roshani D. Prevalence of Hepatitis C Virus Genotypes in Iranian Patients: A Systematic Review and Meta-Analysis. Hepat Mon 2014; 14(12): e22915.
[28] Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L. Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol 2004; 74(2): 246-52.
[29] Jahanbakhsh Sefidi F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepat Mon 2013; 13(1): e7991.
[30] Ziyaeyan M, Alborzi A, Jamalidoust M, Badiee P, Moeini M, Kadivar A. Prevalence of hepatitis C virus genotypes in chronic infected patients, southern Iran. Jundishapur J Microbiol 2011; 4(3): 141-6.
[31] Ziyaeyan M, Jamalidoust M, Moeini M. Evaluation of Hepatitis C Virus Infection in Antibody Positive Orphan Newborns. Jundishapur J Microbiol 2013; 6(1): 72-5.
[32] Jamalidoust M, Namayandeh M, Moghadami M, Ziyaeyan M. Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users. Virol J 2017; 14(1): 127.
[33] Moini M, Ziyaeyan M, Aghaei S, Sagheb MM, Taghavi SA, Moeini M, Jamalidoust M, Hamidpour L. Hepatitis C virus (HCV) infection rate among seronegative hemodialysis patients screened by two methods; HCV core antigen and polymerase chain reaction. Hepat Mon 2013; 13(6): e9147.
[34] Harris KA, Gilham C, Mortimer PP, Teo CG. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol 1999; 58(2): 127-31.
[35] Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61(1 Suppl): S45-57.
[36] Franciscus A. HCV Genotype, Quasispecies & Subtype. HCSP Fact Sheet, 2016; p: 1-3. Available from: http://hcvadvocate.org/ hepatitis/factsheets_pdf/genotype.pdf
[37] Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49(4): 1335-74.
[38] Kwon YC, Ray RB, Ray R. Hepatitis C virus infection: establishment of chronicity and liver disease progression. EXCLI J 2014; 13: 977-96.
[39] Horner SM. Activation and evasion of antiviral innate immunity by hepatitis C virus. J Mol Biol 2014; 426(6): 1198-209.
[40] Shrivastava S, Raychoudhuri A, Steele R, Ray R, Ray RB. Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes. Hepatology 2011; 53(2): 406-14.
[41] Kim H, Bose SK, Meyer K, Ray R. Hepatitis C virus impairs natural killer cell-mediated augmentation of complement synthesis. J Virol 2014; 88(5): 2564-71.
[42] Dhawan VK. Hepatitis C virus [Drugs & Diseases]. Medscape 2016. Available from: emedicine.medscape.com/article/177792-overview. Hepatitis C - Medscape eMedicine
[43] Yang N, Ekanem NR, Sakyi CA, Ray SD. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics. Adv Drug Deliv Rev 2015; 81: 62-74.
[44] Li L, Xu J, Yang D, Tan X, Wang H. Computational approaches for microRNA studies: a review. Mamm Genome 2010; 21(1-2): 1-12.
[45] Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368(18): 1685-94.
[46] Hennessy E, O'Driscoll L. Molecular medicine of microRNAs: structure, function and implications for diabetes. Expert Rev Mol Med 2008; 10: e24.
[47] Mishra PJ. MicroRNAs as promising biomarkers in cancer diagnostics. Biomarker Research 2014; 2: 19.
[48]  Thibault PA, Huys A, Dhillon P, Wilson JA. MicroRNA-122-dependent and -independent replication of Hepatitis C Virus in Hep3B human hepatoma cells. Virology 2013; 436(1): 179-90.
[49]  Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013; 10(9): 542-52.
[50]  Cheng JC, Yeh YJ, Tseng CP, Hsu SD, Chang YL, Sakamoto N, Huang HD. Let-7b is a novel regulator of hepatitis C virus replication. Cell Mol Life Sci 2012; 69(15): 2621-33.
[51]  Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol 2009; 50(3): 453-60.
Pathobiology Reserach
Volume 20, Issue 4
December 2018
Pages 1-19